Market Overview

Actavis Confirms Generic NuvaRing Patent Challenge

Actavis (NYSE: ACT) today confirmed that its subsidiary, Warner Chilcott Company LLC, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Ethinyl Estradiol and Etonogestrel Vaginal Ring, 0.015 mg/24 hour and 0.12 mg/24 hour.  Actavis' ANDA product is a generic version of Merck & Co.'s NuvaRing®, which is an estrogen/progestin combination hormonal contraceptive indicated for use by women to prevent pregnancy.

See full press release

Posted-In: News Guidance Financing Contracts Management Global


Related Articles (ACT)

Around the Web, We're Loving...

Get Benzinga's Newsletters